Frank Laukien : Yes, thanks for the question. Good question, I can give you some incremental because of, to your very last point, we already took out about a few orders from China semiconductor out of our backlog because of the probability or of either significant delays or it’s not being feasible to export certain pieces of equipment. So that’s all built into our forecasts. And we took care of that in Q4, if you like, so no additional risks there that we can see at the time. I think it’s the usual balance of risks and opportunities. Yes, it is backlog, we acknowledged that, of course, that backlog will not come to normalized levels, all in one year, there’ll be a two-to-three-year process. It’s continued orders momentum, it’s also in some of the areas where we were concerned, and we’re wondering ourselves whether they would get quite a bit weaker, and while some of them are not growing as fast.
We haven’t seen any pronounced signs of weakness or any signs of real weakness. So it’s just coming the order momentum. And then order momentum in BioSpin, timsTOF and number of areas is very strong we have. So it’s just, yes, it is an unusual number early in the year for us, but I would think it’s the usual good balance that we hopefully will not regret, right? We, that’s the number that we hope we can deliver.
Patrick Donnelly: Okay, that’s helpful. And then yes, I think this quarter, particularly, there’s been an increased focus on kind of the 1Q and annual progression. Most of your life science peers have kind of guided 1Q to be a little bit light of expectations in the latest quarter as you think about kind of the growth progression throughout the year. Can you guys just give us some perspective on kind of the cadence throughout the year? How should we think about 1Q both on the organic growth side, and then Gerald, maybe on the margin side, just in terms of the build as we work our way through the particularly again, 1Q just given some headwinds via China?
Frank Laukien : We expect Q1, yes, sorry, we also expect Q1 to be a little lighter. So, Gerald, do you want to expand there on some quarterly color but we do acknowledge that we also expect Q1 to be on the lighter side, but we still expect decent growth.
Gerald Herman : Yes, we do. And I would say, from an organic growth perspective, we still expect H1 to be very solid, Q1 may be a little lighter. But remember, we are targeting some ultra-high field systems as we move through the years. So it didn’t get €“
Frank Laukien : I think Q1.
Gerald Herman : Sorry Q1, but it is clear that there’ll be strength in the first half for sure. And in addition, you likely know, we had some supply chain constraints. And we hope to be able to release some of that as we move through the first half, including the first quarters so.
Frank Laukien : And maybe I’ll add to that for your modeling, Q1 of last year was very strong. So we’re likely to be flat or down on margin compared to Q1 of last year, Q2 of last year was particularly supply chain constrained, so Q2 will be a weaker comparison for us. We don’t expect to, we expect to have a more even revenue and margin flow this year than last year. So last year, Q1, strong comparison Q2, weaker comparison, and we expect that to even out in more — be more even in 2023. So for your modeling, relatively speaking, our Q1 will not be that strong, because Q1 of €˜22 was so strong. I hope that help.
Patrick Donnelly: So again on growth side, maybe 1Q below that 8 to 10, maybe like mid-single and then we build our way through the year. Is that kind of a fair ballpark?
